-
Mashup Score: 14
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7RCC: Treatment Goals in the Third-Line Setting - 6 day(s) ago
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Immunotherapy-TKI Combo More Effective for Intermediate-Risk RCC - Renal and Urology News - 9 day(s) ago
Investigators question the usefulness of TKI-IO combinations in poor-risk disease.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Adjuvant Pembrolizumab Prolongs Overall Survival in Clear Cell RCC - Renal and Urology News - 16 day(s) ago
One in 5 patients treated with adjuvant pembrolizumab experienced serious adverse events, so it remains important to weigh the risk vs benefits of the therapy for each individual patient.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC - 25 day(s) ago
NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma With @montypal of @cityofhope, @DrTHut, @DrRanaMcKay of @UCSDHealth, and Benjamin Gerendash, MSN, RN, AGACNP-BC. #KCSM https://t.co/qcCZP3qsK1